RELMADA THERAPEUTICS, INC. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K was filed on November 13, 2025, by Relmada Therapeutics, Inc. (RLMD), a Nevada corporation trading on the NASDAQ Capital Market. The filing serves as a current report to announce the issuance of a press release containing preliminary, unaudited financial results for the third fiscal quarter ended September 30, 2025. The filing also includes an updated corporate presentation.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the financial results are preliminary and unaudited. Complete unaudited financial statements and notes for the three and nine months ended September 30, 2025, and 2024, are reserved for the upcoming Quarterly Report on Form 10-Q.
Material Changes
No specific material changes in financial condition or operations are detailed within the text of this 8-K. The document functions as a notification that such results have been released via a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2).
Guidance, Outlook, and Management Commentary
Management announced a conference call and audio webcast scheduled for November 13, 2025, at 4:30 PM EST to discuss the corporate update and financial results. The filing notes that the information provided in this 8-K and its exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the upcoming Form 10-Q for the period ended September 30, 2025.
- Review the press release (Exhibit 99.1) for details on clinical trial progress or corporate updates not included in this summary.
- Confirm the date and access details for the conference call to hear management's commentary on the preliminary results.
- Check the updated corporate presentation (Exhibit 99.2) for any changes to the company's strategic outlook or pipeline status.